AbbVie hits all-time highs on strong 2026 guidance, Skyrizi and Rinvoq growth, and leading margins. Click here to read this ...

Adaptive Biotechnologies gains from new myeloma MRD guidelines, strong clonoSEQ growth, and refinancing tailwinds. Read why ...

Your immune system is a double-edged sword. We explore how thymosin alpha-1 helps maintain balance, diving into COVID, cancer, and aging, along with practical tools to support a healthy immune system.

ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor ...

Torvu-Sam is moving into phase 3 trials at a dose of 2 mg/kg. In PROC, it will be compared with mirvetuximab soravtansine in ...

Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth –– ARCALYST 2026 expected net ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

Nausea, vomiting, diarrhea and constipation are the price many people pay for the remarkable weight loss and blood sugar ...

A cross-sectional study of 87 Chinese preschoolers finds that living at high altitude, not ethnicity, is strongly associated ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted ...

Zymeworks announced a global collaboration and license agreement giving Roche exclusive worldwide rights to develop and ...

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 ...